Bristol goes pivotal with SystImmune-partnered conjugate
The first global pivotal trial will be in first-line triple-negative breast cancer.
The first global pivotal trial will be in first-line triple-negative breast cancer.
The group expects to raise nearly $170m.
The private group taps DualityBio for an EGFR x HER3 ADC.
But the group is going up against the likes of Merck/Daiichi, Bristol Myers Squibb and BioNTech.
Conferences ramp up, and ASH abstracts near.